Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable’ Evidence Bar™ ratings from ECRI for pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most recently published clinical evidence and key outcomes for pressure injury prevention.
The ECRI Evidence Bar provides a visual representation of ECRI’s view of the benefits and harms of the technology. Their reports, ratings and conclusions do not constitute a recommendation or endorsement of any product or technology. ECRI is an independent and non-profit organization focused on improving the safety, quality, and cost-effectiveness of health care globally. ECRI’s Clinical Evidence Reports are utilized by third-party payers and health care providers as a means of making informed and objective evidence-based decisions.
Smith+Nephew’s ALLEVYN LIFE Sacrum Foam Dressing is indicated to manage chronic and acute exudative and granulating wounds on the sacrum and to help prevent sacral pressure injuries. The dressing has a multilayer design that includes a hydrocellular foam pad that indicates when the dressing requires changing,1,2 a perforated adhesive wound contact layer1,3,4 coated with silicone gel, a showerproof breathable outer layer, an absorbent lock-away core,5,6 and a masking layer to hide the exudate.1,2 Due to independent and non-bonded internal layers of the ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissipation of mechanical energy that could otherwise be transferred to the patient. This distinct mode of action could help alleviate pressure injury incidence in a patient's skin and in the underlying soft tissues.7
Smith+Nephew’s LEAF Patient Monitoring System is a wearable, wireless solution that meets the recommendations in the National Pressure Injury Advisory Panel (NPIAP) guidelines.8 The LEAF System is proven to help improve adherence to individualized turn protocols up to 98%9,10 and has been shown to help reduce the odds of developing hospital-acquired pressure injuries (HAPIs) by 73%.10†
Use of the LEAF System helped improve nursing efficiencies,11,12 and generated up to $1.8 million estimated annual cost savings in one facility's critical care units.11,13
“Hospital-acquired pressure injuries represent a significant burden to global healthcare systems and cost an estimated 60,000 lives14 and $26.8 billion15 in the US each year.” said Rohit Kashyap, President Advanced Wound Management at Smith+Nephew. “The ECRI ‘favorable’ rating for both our ALLEVYN LIFE Sacral Foam Dressing and LEAF Patient Monitoring System further demonstrates Smith+Nephew’s commitment to improving healthcare practices and outcomes in pressure injury prevention.”
ALLEVYN LIFE Foam Dressings and the LEAF Patient Monitoring System are part of Smith+Nephew’s comprehensive Advanced Wound Management portfolio – shaping what’s possible in wound care. To learn more about Smith+Nephew’s pressure injury prevention solutions, please click here.
* ECRI Evidence Bar™ Definition: A visualization of ECRI’s judgement about the balance of benefits and harms of the technology after assessing the available published clinical evidence in light of key outcomes and comparisons of interest.
† p=0.012
References
Tiscar-González V, Menor-Rodríguez MJ, Rabadán-Sainz C, et al. Clinical and Economic Impact of Wound Care Using a Polyurethane Foam Multilayer Dressing. Adv Skin Wound Care. 2021;34(1):23-30.
Simon D, Bielby A. A structured collaborative approach to appraise the clinical performance of a new product. Wounds UK. 2014;10(3):80 - 87.
Smith+Nephew 2016.Product Performance of Next Generation ALLEVYN Life Internal Report. (HVT080) GMCA-DOF/08.
Smith+Nephew 2016.Permeability of Hydrophillic Polyurethane Film when in contact with water and water vapour (ALLEVYN LIFE). Internal Report. RD/16/019.
Smith+Nephew 2016.Wound Model Testing of New ALLEVYN Life Gen2 wcl Dressing using Horse Serum at a Flow Rate Modelling that of a Moderately Exuding Wound. DS/14/303/R.
Marché C, Creehan S, Gefen A. The frictional energy absorber effectiveness and its impact on the pressure ulcer prevention performance of multilayer dressings. Int Wound J. 2024; 21(4):e14871.
European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed.) EPUAP/NPIAP/PPPIA: 2019.
Schutt SC, Tarver C, Pezzani M. Pilot study: Assessing the effect of continual position monitoring technology on compliance with patient turning protocols. Nurs Open. 2017;5(1):21-28.
Pickham D, Berte N, Pihulic M, Valdez A, Mayer B, Desai M. Effect of a wearable patient sensor on care delivery for preventing pressure injuries in acutely ill adults: A pragmatic randomized clinical trial (LS-HAPI study). Int J Nurs Stud. 2018;80:12-19.
Rogers M. Reducing Hospital-Acquired Pressure Injuries (HAPI) in Long-term Acute Care with Turn Cueing Technology. Poster presented at: American Organization for Nursing Leadership; March 18- March 21, 2020; Nashville, Tennessee, USA.
Gasparini R, Derisma Q, Hannon R. “Turning” to Technology: Reducing Hospital Acquired Pressure Injuries in Critical Care with Visual Turn Cueing. Poster presented at: National Pressure Injury Advisory Panel Annual Conference; March 10- March 12, 2021; Virtual Conference.
Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. Int Wound J. 2019;16(3):634-640.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
